VERA
Vera Therapeutics, Inc.
$29.73
-0.52
(-1.72%)
Mkt Cap
2.13B
Volume
1,731,256
52W Range
23.05-56.05
Sector
Healthcare
Beta
0.95
EPS (TTM)
-5.86 USD
P/E Ratio
-10.87
Revenue (TTM)
0 USD
Rev Growth (5Y)
N/A
EPS Growth (5Y)
N/A
Company Description
Vera Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of treatments for significant immunological disorders, primarily within the United States. Their leading therapeutic candidate is atacicept, a fusion protein that patients self-administer as a subcutaneous injection. This drug is currently undergoing Phase IIb clinical trials to treat immunoglobulin A nephropathy. The company is also advancing MAU868, a monoclonal antibody in Phase 2 clinical development, designed to combat BK viremia infections. Founded in 2016 and based in Brisbane, California, the organization operated as Trucode Gene Repair, Inc. until it rebranded to Vera Therapeutics, Inc. in April 2020.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (299.62M) | (152.15M) | (95.99M) | (89.06M) | (32.61M) | (53.41M) | (11.85M) |
| EPS | -4.66 | -2.75 | -2.25 | -3.35 | -2.43 | -14.40 | -3.46 |
| Free Cash Flow | (241.73M) | (135.65M) | (92.24M) | (67.66M) | (23.71M) | (34.91M) | (10.41M) |
| FCF / Share | -3.76 | -2.45 | -2.16 | -2.55 | -1.76 | -9.41 | -3.04 |
| Operating CF | (241.10M) | (134.68M) | (92.18M) | (67.60M) | (23.71M) | (34.81M) | (10.29M) |
| Total Assets | 734.73M | 655.68M | 175.55M | 131.44M | 83.75M | 54.55M | 5.38M |
| Total Debt | 77.31M | 54.64M | 53.71M | 31.29M | 4.92M | 2,000 | 132,000 |
| Cash & Equiv | 354.73M | 92.65M | 45.68M | 43.46M | 79.67M | 53.65M | 3.19M |
| Book Value | 604.52M | 577.15M | 101.69M | 76.91M | 69.59M | (89.35M) | (36.55M) |
| Return on Equity | -0.50 | -0.26 | -0.94 | -1.16 | -0.47 | N/A | N/A |
| Metric | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (109.47M) | (121.03M) | (91.10M) | (80.29M) | (76.53M) | (51.69M) | (43.42M) | (46.63M) | (33.71M) | (28.38M) | (25.66M) | (20.10M) |
| EPS | -1.52 | -1.69 | -1.39 | -1.26 | -1.20 | -0.81 | -0.85 | -0.85 | -0.62 | -0.56 | -0.58 | -0.45 |
| Free Cash Flow | (100.25M) | (106.67M) | (70.10M) | (62.04M) | (55.01M) | (54.59M) | (39.83M) | (37.12M) | (24.87M) | (33.83M) | (25.21M) | (22.97M) |
| FCF / Share | -1.40 | -1.49 | -1.09 | -0.97 | -0.86 | -0.86 | -0.73 | -0.68 | -0.45 | -0.66 | -0.57 | -0.52 |
| Operating CF | (100.25M) | (106.50M) | (69.99M) | (61.91M) | (54.80M) | (54.41M) | (39.18M) | (36.88M) | (24.78M) | (33.83M) | (25.14M) | (22.97M) |
| Total Assets | 532.98M | 621.74M | 734.73M | 517.50M | 578.53M | 610.17M | 655.68M | 368.56M | 397.29M | 419.36M | 175.55M | 175.62M |
| Total Debt | 75.23M | 75.03M | 77.31M | 77.22M | 77.55M | 54.47M | 54.64M | 54.91M | 52.83M | 53.26M | 53.71M | 29.52M |
| Cash & Equiv | 48.88M | 114.35M | 354.73M | 57.77M | 49.12M | 55.09M | 92.65M | 27.26M | 25.09M | 69.11M | 45.68M | 27.44M |
| Book Value | 407.76M | 499.70M | 604.52M | 398.88M | 468.28M | 535.00M | 577.15M | 289.06M | 327.87M | 353.54M | 101.69M | 123.71M |
| Return on Equity | -0.27 | -0.24 | -0.15 | -0.20 | -0.16 | -0.10 | -0.08 | -0.16 | -0.10 | -0.08 | -0.25 | -0.16 |
VERA News
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Vera Therapeutics Announces ORIGIN 3 Final Efficacy Analysis of TRUTAKNA™ (atacicept-vymj) in IgA Nephropathy Will be A Featured Late-breaking Oral Presentation at the Opening Plenary Session of ASN Kidney Week 2026
Vera Therapeutics, Inc. (VERA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
What's Going on With Vera Therapeutics Stock on Tuesday?
Why Vera Therapeutics Stock Is Jumping on New Kidney Drug Trial Results
Why is Vera Therapeutics stock reversing its premarket gains?
Vera Stock Slides Despite Positive Phase 3 Results
Vera Therapeutics Announces TRUTAKNA™ (atacicept-vymj) Stabilized eGFR and Prevented Kidney Disease Progression Through Two Years in ORIGIN 3 Final Efficacy Analysis in IgA Nephropathy
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Vera Therapeutics to Participate at Upcoming Investor Conferences